The stock of Recursion Pharmaceuticals (RXRX) has gained >15% in early trading today, as the AI-driven drug discovery company shared a couple of notable updates. Firstly Recursion announced the ...

Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.

Recent insider activity for Recursion Pharmaceuticals Inc included 1 Tax Payment by Ben R Taylor totaling $18,400.36. 1 transaction was reported, and the full verified total matches $18,400.36.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Suzanne is a content marketer, writer, and fact-checker. She holds a Bachelor of Science in Finance degree from Bridgewater State University and helps develop content strategies. Learn about our ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

RXRX is trading in the middle of its 52-week range and near its 200-day simple moving average. Price change The price of RXRX shares has increased $0.02 since the market last closed. This is a 0.57% ...

New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in ...

Ricursive Intelligence founders Anna Goldie and Azalia Mirhoseini believe more efficient AI chip design could help solve the compute crisis. The founders took the stage at TechCrunch Disrupt on ...